Detalles de la búsqueda
1.
Survey on the working, training, and research conditions of resident physicians in internistic and rheumatological continuing education-BEWUSST.
Z Rheumatol
; 83(Suppl 1): 31-39, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37847298
2.
[Survey on the working, training, and research conditions of resident physicians in internistic and rheumatological continuing education-BEWUSST]. / Befragung zu den Arbeits-, Weiterbildungs- und Forschungsbedingungen von Assistenzärztinnen und -ärzten in der internistisch-rheumatologischen Weiterbildung BEWUSST.
Z Rheumatol
; 2023 Aug 11.
Artículo
en Alemán
| MEDLINE | ID: mdl-37566120
3.
[Rheumatology training positions in Germany]. / Rheumatologische Weiterbildungsstellen in Deutschland.
Z Rheumatol
; 82(7): 539-551, 2023 Sep.
Artículo
en Alemán
| MEDLINE | ID: mdl-36264331
4.
Prevention and management of herpes zoster in patients with rheumatoid arthritis and psoriatic arthritis: a clinical review.
Clin Exp Rheumatol
; 40(1): 162-172, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34128786
5.
Assessment of radiographic progression in patients with rheumatoid arthritis treated with tofacitinib in long-term studies.
Rheumatology (Oxford)
; 60(4): 1708-1716, 2021 04 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33057725
6.
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5â years: integrated analysis of data from the global clinical trials.
Ann Rheum Dis
; 76(7): 1253-1262, 2017 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-28143815
7.
Partial remission in ankylosing spondylitis and non-radiographic axial spondyloarthritis in treatment with infliximab plus naproxen or naproxen alone: associations between partial remission and baseline disease characteristics.
Rheumatology (Oxford)
; 55(11): 1946-1953, 2016 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-27411482
8.
Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab.
Rheumatology (Oxford)
; 55(8): 1466-76, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27114562
9.
[Model curriculum of the German Society for Rheumatology for advanced training in the discipline internal medicine and rheumatology]. / Mustercurriculum der Deutschen Gesellschaft für Rheumatologie für die Weiterbildung im Fachgebiet Innere Medizin und Rheumatologie.
Z Rheumatol
; 80(7): 688-691, 2021 09.
Artículo
en Alemán
| MEDLINE | ID: mdl-34297173
10.
Model curriculum of the German society for Rheumatology for advanced training in the discipline internal medicine and rheumatology. English version.
Z Rheumatol
; 80(Suppl 2): 64-67, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34605981
11.
Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis.
Ann Rheum Dis
; 74(3): 564-8, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25550337
12.
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.
Lancet
; 381(9865): 451-60, 2013 Feb 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-23294500
13.
Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.
Lancet
; 382(9906): 1705-13, 2013 Nov 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-24035250
14.
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.
Ann Rheum Dis
; 73(6): 1020-6, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24595547
15.
Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial.
Ann Rheum Dis
; 73(2): 349-56, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23361084
16.
Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study.
Ann Rheum Dis
; 73(8): 1477-86, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-23740226
17.
German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs.
Rheumatol Int
; 34(1): 1-9, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23942828
18.
Determinants of tofacitinib discontinuation in adult patients with rheumatoid arthritis during long-term extension studies up to 9.5 years.
Rheumatol Adv Pract
; 8(2): rkae063, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38854417
19.
Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study.
Arthritis Rheum
; 64(10): 3156-67, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22806399
20.
Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160.
Ann Rheum Dis
; 71(10): 1671-9, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22459542